Health-related quality of life with tralokinumab in moderate-to-severe atopic dermatitis

Silverberg, Jonathan I.; Guttman‐Yassky, Emma; Gooderham, Melinda; Worm, Margitta; Rippon, Stephanie; O’Quinn, Sean; Merwe, René van der; Kragh, Nana; Kurbasic, Azra; Wollenberg, Andreas

doi:10.1016/j.anai.2020.12.004

Cited by 19 publications

(23 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 2 The MCS, PCS, and all eight domains of the SF-36v2 were improved in patients treated with tralokinumab. 2 ^6666 Among all doses of tralokinumab, sleep interference was improved at week 12. 2 Not reported Phase II, double-blind, randomized, placebo-controlled trial 7 215 adults were randomized 1:1, tralokinumab 300 mg and placebo every two weeks 7 16 weeks Tralokinumab treated patients produced a similar immune response to Tdap (91.9% vs 96.1%) and meningococcal (86.0% vs 84.2%) vaccines compared to placebo at week 16 7 The rate of AEs was lower in the tralokinumab group than the placebo group.…”

Section: Resultsmentioning

confidence: 91%

“… 6 Upper respiratory tract infection, conjunctivitis, headache, and injection-site reaction were reported more often in the tralokinumab group than placebo group. Most of the AEs were mild or moderate and resolved by the end of the study 6 PhaseIIb, randomized, double-blind, placebo-controlled, dose-ranging study 2 204 adults with moderate-to-severe AD received subcutaneous tralokinumab or placebo (1:1:1:1, 45 mg, n = 50; 150 mg, n = 51; 300 mg, n = 52) every two weeks along with a class three TCS cream or ointment at least once daily 2 12 weeks Patients treated with tralokinumab 300 mg had improved DLQI scores at week 12 versus baseline. 2 The MCS, PCS, and all eight domains of the SF-36v2 were improved in patients treated with tralokinumab.…”

Section: Resultsmentioning

confidence: 99%

“… 1 AD is associated with pain, sleep disruption, anxiety, and depression and may contribute to a substantial disease burden among patients. 2 New treatments for AD target the inflammatory pathways driving its pathogenesis, improving the physical and mental well-being of patients. 2 …”

Section: Introductionmentioning

confidence: 99%

“… 2 New treatments for AD target the inflammatory pathways driving its pathogenesis, improving the physical and mental well-being of patients. 2 …”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Therapeutic Potential of Tralokinumab in the Treatment of Atopic Dermatitis: A Review on the Emerging Clinical Data

Kelly¹,

Perche²,

Feldman³

2022

CCID

View full text Add to dashboard Cite

Atopic dermatitis (AD) is a chronic inflammatory skin disease that greatly impacts patient quality of life. Type 2 cytokine interleukin (IL)-13 is integral to the pathogenesis of AD. Tralokinumab is a fully human IgG4 monoclonal antibody that specifically targets IL-13, preventing downstream signaling of inflammatory pathways that may contribute to AD. Tralokinumab was US Food and Drug administration (FDA) recently approved for the treatment of moderate to severe AD on December 28, 2021. In our review, we will explore the efficacy and adverse effects (AEs) of tralokinumab for the treatment of patients with moderate to severe AD. A PubMed search for key articles on the emerging clinical data of tralokinumab was performed. Six randomized controlled trials of tralokinumab identified improvements in disease severity measures, including Investigator’s Global Assessment (IGA) scores and Eczema Area Severity Index 75 (EASI75) scores. Four of these studies demonstrated improvements in quality of life measures with tralokinumab, including pruritus scores, sleep interference scores, Dermatology Life Quality Index, SCORing Atopic Dermatitis (SCORAD), Patient Oriented Eczema Measure, and The Short Form 36 Health Survey (SF-36v2) scores. One study identified a similar immune response in patients taking tralokinumab to those taking the Tdap and meningococcal vaccines. Upper respiratory infection, conjunctivitis, and headaches were the most common adverse events. The varying criteria to assess changes in AD disease severity across different studies is a limitation of this review. Tralokinumab is another promising biologic option for the treatment of moderate to severe AD, which may reduce disease burden and improve patient quality of life.

show abstract

Section: Resultsmentioning

confidence: 91%

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

“… 2 New treatments for AD target the inflammatory pathways driving its pathogenesis, improving the physical and mental well-being of patients. 2 …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Therapeutic Potential of Tralokinumab in the Treatment of Atopic Dermatitis: A Review on the Emerging Clinical Data

Kelly¹,

Perche²,

Feldman³

2022

CCID

View full text Add to dashboard Cite

show abstract

“…Tralokinumab improved health-related QoL in patients with moderate-to-severe AD, providing further evidence of the value of targeting interleukin-13 in such patients. 146…”

Section: Subcutaneous Agentsmentioning

confidence: 99%

Experimental Drugs with the Potential to Treat Atopic Eczema

Hon¹,

Chan²,

Leung

2021

JEP

View full text Add to dashboard Cite

Introduction: Eczema or atopic dermatitis (AD) is a chronically relapsing dermatosis characterized by pruritus and a significant impact on the quality of life. Methods: The authors undertook a structured search of peer-reviewed research articles from PubMed and Google Scholar. Recent and up-to-date studies relevant to the topic were included. Results: This report overviews current treatment and experimental drug for AD. Topical agents including topical phosphodiesterase E4 (PDE4) inhibitors such as crisaborole are efficacious in the treatment of AD with few side effects. Monoclonal antibodies such as dupilumab given subcutaneously are efficacious for more severe disease. Systemic treatment can ameliorate symptoms in severe and recalcitrant AD. New systemic treatment includes several traditional herbal formulations that have undergone clinical trials using modern research methodology to determine their efficacy and safety. AD is associated with many complicating psychosocial issues. Often suboptimal efficacy is due to unrealistic expectations and poor compliance making treatment difficult in spite of effective treatment and efforts in drug discovery. Randomized trials have shown that novel topical and subcutaneous medications are safe and efficacious. Regarding herbs, a methodology for the investigation of herbal medications is often flawed and scientific evidence is lacking. Experimental drugs include various biologics, PDE4 and JAK inhibitors in topical, oral, subcutaneous or intravenous forms are in various phases of trials. Conclusion: Many novel medications demonstrate efficacy for AD. Experimental drugs include various biologics, PDE4 and JAK inhibitors are in various phases of trials.

show abstract

Atopic dermatitis: pathogenesis and therapeutic intervention

Yue,

Zhou,

Wang

et al. 2024

MedComm

View full text Add to dashboard Cite

The skin serves as the first protective barrier for nonspecific immunity and encompasses a vast network of skin‐associated immune cells. Atopic dermatitis (AD) is a prevalent inflammatory skin disease that affects individuals of all ages and races, with a complex pathogenesis intricately linked to genetic, environmental factors, skin barrier dysfunction as well as immune dysfunction. Individuals diagnosed with AD frequently exhibit genetic predispositions, characterized by mutations that impact the structural integrity of the skin barrier. This barrier dysfunction leads to the release of alarmins, activating the type 2 immune pathway and recruiting various immune cells to the skin, where they coordinate cutaneous immune responses. In this review, we summarize experimental models of AD and provide an overview of its pathogenesis and the therapeutic interventions. We focus on elucidating the intricate interplay between the immune system of the skin and the complex regulatory mechanisms, as well as commonly used treatments for AD, aiming to systematically understand the cellular and molecular crosstalk in AD‐affected skin. Our overarching objective is to provide novel insights and inform potential clinical interventions to reduce the incidence and impact of AD.

show abstract

Health-related quality of life with tralokinumab in moderate-to-severe atopic dermatitis

Cited by 19 publications

References 29 publications

Therapeutic Potential of Tralokinumab in the Treatment of Atopic Dermatitis: A Review on the Emerging Clinical Data

Therapeutic Potential of Tralokinumab in the Treatment of Atopic Dermatitis: A Review on the Emerging Clinical Data

Experimental Drugs with the Potential to Treat Atopic Eczema

Atopic dermatitis: pathogenesis and therapeutic intervention

Contact Info

Product

Resources

About